Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$1.20M$1.20M+474.5% vs Q3 2021 Net Income-$28.91M-$28.91MN/M vs Q3 2021 EPS Diluted-$0.86-$0.86N/M vs Q3 2021 Operating Income-$29,785,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,763,000N/M Margins · derivedOperating margin-2492.5%+4302.7 pt vs Q3 2021
Net margin-2418.8%+4332.6 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end